We are live on ! Find out more
DMRA

Damora Therapeutics, Inc. Ordinary Shares
DMRA

26 hedge funds and large institutions have $17.8M invested in Damora Therapeutics, Inc. Ordinary Shares in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more call options, than puts

Call options by funds: $18K | Put options by funds: $2K

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

74% more capital invested

Capital invested by funds: $10.2M → $17.8M (+$7.61M)

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

18% more funds holding

Funds holding: 22 → 26 (+4)

0.01% more ownership

Funds ownership: 1.39% → 1.4% (+0.01%)

Holders
26
Holders Change
+4
Holders Change %
+18.18%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
5
Reduced
3
Closed
1
Calls
$18K
Puts
$2K
Net Calls
+$16K
Net Calls Change
+$4K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$56.1K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$53.4K
3
MCM
MAI Capital Management
Ohio
+$46.8K
4
TCOT
Trust Company of Toledo
Ohio
+$25.3K
5
Citadel Advisors
Citadel Advisors
Florida
+$10.2K

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Advisers
Two Sigma Advisers
New York
-$19K
2
TRCT
Tower Research Capital (TRC)
New York
-$8.65K
3
Two Sigma Investments
Two Sigma Investments
New York
-$6.12K
4
ACP
Arcus Capital Partners
Georgia
-$557
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$8.14M – – –
NHAS
2
Novo Holdings A/S
Denmark
$4.97M – – –
CAM
3
Cormorant Asset Management
Massachusetts
$2.03M – – –
MCM
4
MAI Capital Management
Ohio
$508K +$46.8K +887 +10%
LCM
5
Laurion Capital Management
New York
$379K – – –
BCM
6
Bridgeway Capital Management
Texas
$344K – – –
Renaissance Technologies
7
Renaissance Technologies
New York
$311K +$4.43K +84 +1%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$217K – – –
Federated Hermes
9
Federated Hermes
Pennsylvania
$199K – – –
Vanguard Group
10
Vanguard Group
Pennsylvania
$132K +$56.1K +1,063 +67%
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
$125K +$53.4K +1,012 +67%
Two Sigma Advisers
12
Two Sigma Advisers
New York
$107K -$19K -360 -14%
Bank of America
13
Bank of America
North Carolina
$104K +$5.01K +95 +5%
State Street
14
State Street
Massachusetts
$89.4K – – –
Northern Trust
15
Northern Trust
Illinois
$40.9K – – –
BlackRock
16
BlackRock
New York
$33.2K – – –
Two Sigma Investments
17
Two Sigma Investments
New York
$28.9K -$6.12K -116 -17%
TCOT
18
Trust Company of Toledo
Ohio
$23.9K +$25.3K +480 New
Citadel Advisors
19
Citadel Advisors
Florida
$9.65K +$10.2K +194 New
TRCT
20
Tower Research Capital (TRC)
New York
$7K -$8.65K -164 -54%
Wells Fargo
21
Wells Fargo
California
$4.97K – – –
UBS Group
22
UBS Group
Switzerland
$4.94K +$5.22K +99 New
Northwestern Mutual Wealth Management
23
Northwestern Mutual Wealth Management
Wisconsin
$2.79K +$2.96K +56 New
JP Morgan Chase
24
JP Morgan Chase
New York
$2K – – –
Commonwealth Equity Services
25
Commonwealth Equity Services
Massachusetts
$20 – – –
1
2

DMRA Hedge Fund Activity: Q1 2023 in Review

26 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) for Q1 2023, worth a combined $17.8M — up 74% from $10.2M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new DMRA positions and 1 closed out — a net gain of 4 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was Vanguard Group, adding an estimated $56.1K. The largest seller was Two Sigma Advisers, cutting an estimated $19K.

  • 26 institutional investors held Damora Therapeutics, Inc. Ordinary Shares (DMRA) as of Q1 2023, up from 22 in Q4 2022.
  • Funds reported $17.8M of Damora Therapeutics, Inc. Ordinary Shares stock for Q1 2023, up 74% quarter-over-quarter.
  • 5 funds opened new Damora Therapeutics, Inc. Ordinary Shares positions in Q1 2023 and 1 closed out, a net change of +4 holders.
  • The largest Damora Therapeutics, Inc. Ordinary Shares buyer in Q1 2023 was Vanguard Group, an estimated $56.1K added.
  • The largest Damora Therapeutics, Inc. Ordinary Shares seller in Q1 2023 was Two Sigma Advisers, an estimated $19K sold.

Based on aggregated 13F filings for Q1 2023.